MLN9708 in combination with lenalidomide and dexamethasone

Name: MLN9708 in combination with lenalidomide and dexamethasone
Uploaded: 2012-12-16T14:18:00+00:00
Description: Dr Kumar presents findings during a press conference on phase I study of MLN9708, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma at the 2012 ASH Annual Meeting in Atlanta, Georgia.

ASH 2012

8 - 11 Dec 2012

Published: 16 Dec 2012

Rating:

Save

Dr Shaji Kumar - Mayo Clinic, Rochester, USA

Dr Kumar presents findings during a press conference on phase I study of MLN9708, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma at the 2012 ASH Annual Meeting in Atlanta, Georgia.

Related Videos

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

28 Oct 2024

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies

Prof Joy Ho - The University of Sydney, Sydney, Australia

28 Oct 2024

Guiding transplant decisions in multiple myeloma with MRD

Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA

28 Oct 2024

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients

Prof Salomon Manier - Hospital Center University De Lille, Lille, France

30 Sep 2024

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

30 Sep 2024

Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma

Dr Jeremy Abramson - Mass General Cancer Center, Boston, USA

$Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma ( Dr Jeremy Abramson - Mass General Cancer Center, Boston, USA )$